Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?

F. Cappuzzo
  • JNCI Journal of the National Cancer Institute, June 2005, Oxford University Press (OUP)
  • DOI: 10.1093/jnci/dji169

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1093/jnci/dji169

The following have contributed to this page: Dr Federico Cappuzzo